Articles

Browse normalized, publication-ready research with direct links to its evidence and source.

Loading articles data…

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Readable research linked to original sources

Articles

Browse normalized, publication-ready research with direct links to its evidence and source.

Filters

Clear all

Article type

Publication year

19172026

From yearTo year

Keyword

Active filter

Author: Kristen G. Bzdek

1 articles

Newest first

Research Article 2026CC BYCC BY allows this article to remain publicly readable here. Any reuse must still follow the recorded source terms.Free full text

Phase 2, open-label INSPIRE trial to assess the tolerability and effectiveness of transdermal cannabidiol gel in children and adolescents with 22q11.2 deletion syndrome (ZYN2-CL-031).

Helen Heussler, Jonathan Cohen, Caroline B. Buchanan, David S. Albers, Kristen G. Bzdek

BACKGROUND: 22q11.2 deletion syndrome (22qDS) is a genetic disorder affecting various body systems and associated with behavioral and psychiatric conditions, with no currently approved pharmacological treatments. ZYN002, a transdermal gel containing synthetic cannabidiol, has been demonstrated to be well tolerated, showing potential benefit in related neurodevelopmental disorders. The INSPIRE study evaluated the s…

Journal of Neurodevelopmental Disorders Europe PMC↗

Open article record in new tab ↗

End of results

The service organizes published evidence. It does not provide medical advice.